To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

Inclusion Criteria: 1. Provide signed informed consent； 2. Diagnosis of PsA fulfillment of the Classification Criteria for PsA (CASPAR) criteria with symptom onset at least 6 months prior to the Screening Visit； 3. Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints； 4. Diagnosis of active plaque psoriasis or documented history of plaque psoriasis. Exclusion Criteria: 1. History of other autoimmune diseases; history of cancer or infection including tuberculosis and hepatitis; history of important cardiovascular events or thrombotic diseases； 2. Non-plaque forms of psoriasis (with exception of nail psoriasis)； 3. Previous treatment with cytotoxic drugs; JAK inhibitor or bDMARDs within 6 months of randomization.